Saturday 17 October 2026
Export IMMX’s income statement to Excel — free account
Immix Biopharma, Inc.
IMMX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 18.2% and free cash flow fell 116.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.98
0.70
−8.06%
Follow IMMX
Immix Biopharma, Inc. (IMMX) P/E ratio
Immix Biopharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IVA Inventiva S.A. Sponsored ADR compare | n/m |
| SANA Sana Biotechnology, Inc. compare | n/m |
| ACHV Achieve Life Sciences, Inc. compare | n/m |
| FDMT 4D Molecular Therapeutics, Inc. compare | n/m |
| OABI OmniAb, Inc. compare | n/m |
| ANNX Annexon, Inc. compare | n/m |
| IMMX Immix Biopharma, Inc. | n/m |
| LXRX Lexicon Pharmaceuticals, Inc. compare | n/m |
| ANL Adlai Nortye Ltd. Sponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)